2025
article
OpenAlex
Akpedje Serena Dossou, Tahira Kalhoro, Eduardo Castro Echeverry, Nathan C. Horton
Accès ouvert
2025
article
OpenAlex
Akpedje Serena Dossou, Tahira Kalhoro, Eduardo Castro-Echeverry, Nathan C. Horton
Background/Objectives: Adalimumab and Infliximab are biologics used to treat autoimmune diseases. Monitoring drug and anti-drug antibody (ADA) levels in patients helps optimize treatment. However, current quantitation methodologies for drug and total (free and drug-bound) ADAs often involve multi-step workflows. Automated systems can …
Accès ouvert
2025
article
OpenAlex
André Otti, 2.Beninese Society of Nursing Sciences (SOBESI), Akpedje Serena Dossou, F Seibou. et autres
Introduction: Faced with the highly aversive symptoms and incapacitating side effects of anticancer therapy, the assessment of patients' Quality of Life (QoL) is essential to better inform clinical decisions. Using a mixed design, the QoL of cancer patients followed in the medical …
2025
article
OpenAlex
N. L. Gavade, Shamkumar P. Deshmukh, Akpedje Serena Dossou, Sangram Raut et autres
in, us
(code pays fourni par la source)
2025
book-chapter
OpenAlex
Akpedje Serena Dossou, Nirupama A. Sabnis, Ammar Kapic, Rafał Fudala et autres
us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Ammar Kapic, Nirupama A. Sabnis, Akpedje Serena Dossou, Jose L. Chavez et autres
Cytotoxic activity has been reported for the xanthone α-mangostin (AMN) against Glioblastoma multiforme (GBM), an aggressive malignant brain cancer with a poor prognosis. Recognizing that AMN's high degree of hydrophobicity is likely to limit its systemic administration, we formulated AMN using reconstituted …
us
(code pays fourni par la source)
2024
article
OpenAlex
Nirupama A. Sabnis, Sangram Raut, Bhavani Nagarajan, Ammar Kapic et autres
To meet the current need for a tumor-selective, targeted therapy regimen associated with reduced toxicity, our laboratory has developed a spontaneously assembled nanostructure that resembles high-density lipoproteins (HDLs). These myristoyl-5A (MYR-5A) nanotransporters are designed to safely transport lipophilic pharmaceuticals, including a novel …
us
(code pays fourni par la source)
Accès ouvert
2024
preprint
OpenAlex
N. L. Gavade, Shamkumar P. Deshmukh, Akpedje Serena Dossou, Sangram Raut et autres
in
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Akpedje Serena Dossou, Morgan E. Mantsch, Nirupama A. Sabnis, Rance E. Berg et autres
The targeting and conversion of the immunosuppressive (M2) tumor-associated macrophages (TAMs) to an immunostimulatory (M1) phenotype can induce tumor regression in advanced melanoma. We have previously characterized and reported the ability of reconstituted high-density lipoprotein nanoparticles (rHDL NPs) functionalized with DSPE-PEG-mannose (DPM) …
us
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Akpedje Serena Dossou, Morgan E. Mantsch, Ammar Kapic, W. L. Burnett et autres
Reconstituted high-density lipoprotein nanoparticles (rHDL NPs) have been utilized as delivery vehicles to a variety of targets, including cancer cells. However, the modification of rHDL NPs for the targeting of the pro-tumoral tumor-associated macrophages (TAMs) remains largely unexplored. The presence of mannose …
us
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Andras G. Lacko, Nirupama A. Sabnis, Dorota L. Stankowska, Akpedje Serena Dossou et autres
The primary focus of this review is lipoprotein-based drug carriers, more specifically, high-density lipoprotein (HDL) type nanoparticles (NPs). These nanostructures are discussed regarding their suitability for clinical applications, particularly for cancer therapy. Poor solubility and insufficient capability to selectively target malignant tumors …
us
(code pays fourni par la source)
2023
book-chapter
OpenAlex
Akpedje Serena Dossou, Nirupama A. Sabnis, Ammar Kapic, Rafał Fudala et autres
us
(code pays fourni par la source)